Purpose: Administration of carbamazepine (CBZ) forms a part of the treatment for trigeminal neuralgia. However, administration is sometimes discontinued if patients suffer adverse effects or show drug resistance. We reviewed clinical data on trigeminal neuralgia patients to determine the best therapeutic intervention for this condition.
Methods: We collected data on the age, gender, involved site, head MRI findings, approach to treatment, and side effects in 48 patients at the Department of Dentistry and Oral Surgery at Tokyo Metropolitan Tama Medical Center to determine the current status of trigeminal neuralgia patients.
Results: The age distribution was from 29 to 96 years with the average age of 69.7 years. The patients comprised 11 men (22.9%) and 37 women (77.1%). The most common involved site was the maxillary division of the trigeminal nerve (25 cases, 52.1%). MRI findings (44 cases) revealed the involvement of 18 (40.9%) blood vessel, the most common being the superior cerebellar artery (9 cases or 50%). Three cases of brain cancer were also detected (6.8%), specifically, an acoustic nerve tumor, a meningioma, and an epidermoid tumor. Thirty-four of 45 patients received CBZ, which produced an instant effect. However, the remaining 11 cases required additional treatment. The peak response to CBZ was obtained most frequently at a dosage of 200mg. Fourteen (31.1%) side effects were recognized, the most common of which was wobbling (6 cases).
Conclusion: We reviewed the clinical data of 48 trigeminal neuralgia patients at the Department of Dentistry and Oral Surgery at Tokyo Metropolitan Tama Medical Center. However, we were unable to find specific clinical features enabling identification of patients who experience adverse effects or resistance to CBZ.
View full abstract